PriceTargets.com logo

BioCryst Pharmaceuticals - BCRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.60
  • Forecasted Upside: 107.17%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.53 As of 12/30/2024 06:26 PM ET
▼ -0.18 (-2.33%)

This chart shows the closing price for BCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioCryst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCRX

Analyst Price Target is $15.60
▲ +107.17% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $15.60, with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 107.17% upside from the last price of $7.53.

This chart shows the closing price for BCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in BioCryst Pharmaceuticals. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
11/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/5/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $8.00
8/6/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $16.00
8/6/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/7/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$14.00 ➝ $15.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
1/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$10.00
11/6/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
9/25/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$10.00
9/18/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$9.00 ➝ $10.00
8/4/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$8.00 ➝ $9.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
8/4/2023Jefferies Financial GroupUpgradeHold ➝ Buy$11.00
8/3/2023Needham & Company LLCReiterated RatingBuy$14.00 ➝ $12.00
7/13/2023Bank of AmericaUpgradeNeutral ➝ Buy$10.00
4/20/2023Needham & Company LLCReiterated RatingBuy$14.00
4/20/2023Evercore ISILower TargetOutperform$13.00 ➝ $10.00
3/14/2023Royal Bank of CanadaReiterated RatingSector Perform$10.00
2/22/2023JMP SecuritiesReiterated RatingMarket Outperform$16.00
2/22/2023HC WainwrightReiterated RatingBuy$30.00
2/22/2023Needham & Company LLCUpgradeHold ➝ Buy$14.00
12/16/2022BarclaysLower Target$12.00 ➝ $10.00
11/2/2022Royal Bank of CanadaLower TargetSector Perform$14.00 ➝ $13.00
11/2/2022Evercore ISIUpgradeIn-Line ➝ Outperform$14.00 ➝ $16.00
8/5/2022Evercore ISIDowngradeOutperform ➝ In-Line$14.00
8/5/2022OppenheimerDowngradeOutperform ➝ Market Perform
8/5/2022BarclaysBoost TargetEqual Weight$12.00 ➝ $14.00
5/13/2022OppenheimerLower TargetOutperform ➝ Outperform$16.00 ➝ $13.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
5/5/2022Piper SandlerLower Target$24.00 ➝ $19.00
4/18/2022BarclaysDowngradeOverweight ➝ Equal Weight$22.00 ➝ $13.00
4/12/2022Royal Bank of CanadaLower TargetSector Perform$16.00 ➝ $14.00
4/11/2022OppenheimerLower TargetOutperform$20.00 ➝ $16.00
4/11/2022Bank of AmericaDowngradeBuy ➝ Neutral$21.00 ➝ $14.00
4/8/2022Evercore ISILower Target$25.00 ➝ $15.00
2/24/2022HC WainwrightReiterated RatingBuy$30.00
2/24/2022BarclaysBoost Target$17.00 ➝ $22.00
2/23/2022Piper SandlerReiterated RatingIn-Line$24.00
1/11/2022HC WainwrightReiterated RatingBuy$30.00
12/9/2021OppenheimerInitiated CoverageOutperform$16.00
11/4/2021Royal Bank of CanadaLower TargetSector Perform$16.00 ➝ $14.00
11/4/2021BarclaysLower TargetOverweight$21.00 ➝ $17.00
9/16/2021JMP SecuritiesReiterated RatingBuy$23.00
8/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$19.00
8/6/2021Royal Bank of CanadaBoost TargetSector Perform$13.00 ➝ $16.00
8/6/2021JMP SecuritiesBoost TargetMarket Outperform$22.00 ➝ $23.00
8/6/2021BarclaysBoost TargetOverweight$20.00 ➝ $21.00
8/6/2021HC WainwrightBoost TargetBuy$18.00 ➝ $30.00
8/5/2021Piper SandlerBoost TargetOverweight$18.00 ➝ $22.00
8/3/2021Cantor FitzgeraldInitiated CoverageOverweight$21.00
6/17/2021CowenBoost TargetOutperform$18.00 ➝ $21.00
5/28/2021Piper SandlerBoost TargetOverweight$15.00 ➝ $18.00
5/7/2021Evercore ISIBoost Target$16.00 ➝ $20.00
5/7/2021BarclaysBoost TargetOverweight$13.00 ➝ $20.00
4/15/2021Needham & Company LLCReiterated RatingHold
3/24/2021HC WainwrightBoost TargetBuy$14.00 ➝ $19.00
3/17/2021JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$10.00 ➝ $15.00
3/1/2021CowenInitiated CoverageOutperform$16.00
2/26/2021BarclaysBoost TargetOverweight$9.00 ➝ $13.00
1/22/2021Royal Bank of CanadaBoost TargetSector Perform$7.00 ➝ $9.00
12/7/2020HC WainwrightBoost TargetBuy$13.00 ➝ $14.00
11/23/2020Evercore ISIInitiated CoverageOutperform$12.00
10/4/2020Bank of AmericaReiterated RatingBuy$6.00
9/29/2020JPMorgan Chase & Co.Initiated CoverageOverweight
8/28/2020Royal Bank of CanadaReiterated RatingHold$4.50
8/7/2020HC WainwrightReiterated RatingBuy$13.00
7/6/2020Royal Bank of CanadaReiterated RatingHold$5.00
6/26/2020JMP SecuritiesBoost TargetOutperform$10.00 ➝ $11.00
6/16/2020BTIG ResearchInitiated CoverageNeutral
6/8/2020Piper SandlerReiterated RatingBuy$10.00
5/7/2020Royal Bank of CanadaReiterated RatingHold$4.00
5/6/2020Needham & Company LLCReiterated RatingHold
5/6/2020Piper SandlerBoost Target$8.00 ➝ $10.00
5/5/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.00 ➝ $7.00
3/9/2020Needham & Company LLCReiterated RatingHold
(Data available from 12/30/2019 forward)

News Sentiment Rating

1.37 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 34 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 6 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2024
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 18 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2024
  • 17 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 17 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.53
Low: $7.48
High: $7.71

50 Day Range

MA: $7.64
Low: $7.03
High: $8.43

52 Week Range

Now: $7.53
Low: $4.03
High: $8.88

Volume

1,447,842 shs

Average Volume

2,818,411 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCryst Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on BioCryst Pharmaceuticals in the last twelve months: Barclays PLC, HC Wainwright, JMP Securities, Needham & Company LLC, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for BCRX.

What is the current price target for BioCryst Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for BioCryst Pharmaceuticals in the last year. Their average twelve-month price target is $15.60, suggesting a possible upside of 107.2%. HC Wainwright has the highest price target set, predicting BCRX will reach $30.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $8.00 for BioCryst Pharmaceuticals in the next year.
View the latest price targets for BCRX.

What is the current consensus analyst rating for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BCRX.

What other companies compete with BioCryst Pharmaceuticals?

Other companies that are similar to BioCryst Pharmaceuticals include Halozyme Therapeutics, Ionis Pharmaceuticals, Alkermes, Amicus Therapeutics and Geron. Learn More about companies similar to BioCryst Pharmaceuticals.

How do I contact BioCryst Pharmaceuticals' investor relations team?

BioCryst Pharmaceuticals' physical mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company's listed phone number is (919) 859-1302 and its investor relations email address is [email protected]. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Learn More about contacing BioCryst Pharmaceuticals investor relations.